Hilco is pleased to offer for sale a pioneering UK-based medical technology company operating in the ostomy and chronic bowel care sector (the “Company”). With CE and UKCA-marked products that are clinically validated and approved for NHS prescription via the Drug Tariff, award-winning patient-centric designs, and a highly engaged user community, the Company is redefining standards of functionality, discretion, and dignity for people living with a stoma, and is now well-positioned for commercial scale-up.
Highlights
First-Mover Innovation: A patented, clinically validated ostomy bag system delivering dramatic improvements in leakage prevention, skin protection, and discretion. Trials show 97% of users experienced no skin complications and 79% reported zero leakage, representing a step-change from industry norms.
Proven Regulatory and Market Access: The Company’s products are CE and UKCA-marked and listed on the NHS Drug Tariff and are currently being prescribed. A UK wholesaler relationship is in place, supporting recurring revenue via NHS-funded patient prescriptions.
Digitally Enabled Community and Platform: The Company’s peer-support platform for people living with a stoma has built an active global user base with a 44% weekly engagement rate, six times the sector average, providing an unrivalled channel for direct-to-patient engagement, sample conversion, and customer retention.
High-Potential Brand and Traction: Backed by multiple innovation awards, the brand has generated over 1,000 patient sample requests through organic demand. Approximately 12% of early users have either confirmed intent to convert or already converted, a strong indicator of adoption potential, particularly given the complex lead times in this sector.
Recurring Revenue Model: The Company operates a high-retention, recurring revenue model driven by its disposable ostomy products. With scale, automation, and material efficiencies, gross profit margins are projected to exceed 60% within three years.
Comprehensive IP Portfolio: Four international patent families (including grants in the UK and US), multiple design registrations across major markets, and registered trade marks for core brands, offering layered IP protection across function, design, and brand.
Available Assets
Patented Technology: Four patent families (granted and pending) covering innovations in baseplate design, coupling systems, and product accessories, addressing key challenges around comfort, leak control, and discretion.
Registered Designs and Trade Marks: UK and international registered designs protecting product aesthetics, alongside brand trade marks.
Digital Platform: A globally available, data-rich peer platform designed to support people living with a stoma. Built-in functionality enables future monetisation via advertising, premium subscriptions, and patient engagement insights.
Manufacturing and Supply Chain: UK-based ISO 13485-certified manufacturing partner and an established quality assurance framework.
Regulatory Approvals and Commercial Contracts: CE and UKCA-compliant product range with NHS Drug Tariff listing, established prescription supply infrastructure in the UK, and a US distribution partner for accessories.
Customer Data and Early Revenue: A growing base of active users, a validated prescription-switching pathway, and early NHS-funded sales through UK pharmacy and NHS contractor networks.
This is a rare opportunity to acquire a clinically proven, IP-rich business at the forefront of ostomy care innovation. With clear unmet need, active customer validation, and a globally scalable product set, the Company offers immediate pathways to revenue.
Sales Process
Offers are due Tuesday 27 May 2025 at 4pm BST.
All expressions of interest and bids are to be directed to Hilco in writing. Please contact Hilco to gain access to a virtual data room for further information on signing a confidentiality agreement.
Key Terms & Conditions
Hilco is acting as exclusive agent to the Company in connection with the proposed sale of some or all of the Company’s business and assets (or shares).
All sales are made strictly on an “as seen, where lying” basis. Only such right, title and interest (if any) as the Company may have in the assets will be transferred to a purchaser. No warranties, guarantees, or representations (express or implied) are provided by the Company or Hilco in respect of the assets or any information supplied. All parties must rely on their own enquiries and due diligence. Any information provided is for convenience only and has not been independently verified.
All offers are subject to the addition of VAT at the prevailing rate, where applicable. A non-refundable deposit equal to 20% of the agreed purchase price must be paid by the successful purchaser within 48 hours of offer acceptance. Payment of the deposit grants the purchaser the exclusive right to proceed with the acquisition of the relevant assets for a limited period and on the terms agreed. A Buyer’s Premium of 10% of the final purchase price is payable by the successful purchaser in addition to the agreed purchase price, is non-negotiable and is payable at the same time and in the same manner as the purchase price and forms a condition of sale.
Legal completion must occur within five (5) business days of offer acceptance, unless otherwise agreed in writing by the Company and Hilco. Failure to complete within this period may result in forfeiture of the deposit and termination of the transaction.
